Pharvaris Validates Patient-Reported Outcomes for HAE Treatment in Key Study
Event summary
- Pharvaris published a study in Clinical Reviews in Allergy & Immunology validating patient-reported outcomes (PROs) for hereditary angioedema (HAE) treatment.
- The study assessed PGI and AMRA instruments, confirming their reliability for measuring HAE attack symptoms.
- Results support the hierarchical ranking of endpoints in Pharvaris' Phase 3 RAPIDe-3 trial for deucrictibant.
- Study included real-world data from U.S. HAE patients treating attacks with standard of care.
- Pharvaris aims to submit an NDA for deucrictibant immediate-release capsule in H1 2026.
The big picture
Pharvaris' study addresses a critical gap in HAE treatment evaluation by standardizing patient-reported outcomes, which could set a new benchmark for clinical trials in this rare disease space. The validation of PRO instruments may help differentiate deucrictibant in a market where comparative data has been limited. This development comes as Pharvaris prepares for key regulatory milestones in 2026.
What we're watching
- Regulatory Pathway
- Whether Pharvaris can secure FDA approval for deucrictibant by H1 2026 as planned.
- Clinical Validation
- How the validated PRO instruments will influence future HAE treatment trials.
- Market Differentiation
- The pace at which Pharvaris can establish deucrictibant as a preferred oral alternative to injectable HAE treatments.
Our editorial coverage: